I
Itsuro Shimada
Researcher at Astellas Pharma
Publications - 41
Citations - 814
Itsuro Shimada is an academic researcher from Astellas Pharma. The author has contributed to research in topics: ALK inhibitor & Kinase activity. The author has an hindex of 15, co-authored 41 publications receiving 725 citations.
Papers
More filters
Journal ArticleDOI
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Masamichi Mori,Naoki Kaneko,Yoko Ueno,Masaki Yamada,Ruriko Tanaka,Rika Saito,Itsuro Shimada,Kenichi Mori,Sadao Kuromitsu +8 more
TL;DR: Results indicate that gilteritinib may be an important next-generationFLT3 inhibitor for use in the treatment of FLT3 mutation-positive AML.
Journal ArticleDOI
The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
Masamichi Mori,Yoko Ueno,Satoshi Konagai,Hiroshi Fushiki,Itsuro Shimada,Yutaka Kondoh,Rika Saito,Kenichi Mori,Nobuaki Shindou,Takatoshi Soga,Hideki Sakagami,Takashi Furutani,Hitoshi Doihara,Masafumi Kudoh,Sadao Kuromitsu +14 more
TL;DR: Findings indicate that ASP3026 has potential efficacy for NSCLC and is expected to improve the therapeutic outcomes of patients with cancer with ALK abnormality and exhibited potent antitumor activity against cells expressing EML4-ALK.
Patent
Diamino heterocyclic carboxamide compound
Itsuro Shimada,Kazuo Kurosawa,Takahiro Matsuya,Kazuhiko Iikubo,Yutaka Kondoh,Akio Kamikawa,Hiroshi Tomiyama,Yoshinori Iwai +7 more
TL;DR: In this paper, the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein.
Journal ArticleDOI
Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist
Yasuharu Kimura,Kenichi Hatanaka,Yuki Naitou,Kyoichi Maeno,Itsuro Shimada,Akiko Koakutsu,Fumikazu Wanibuchi,Tokio Yamaguchi +7 more
TL;DR: In conclusion, YM348 is a novel, potent and orally active 5-HT(2C) receptor agonist, and neither the activation of 4-fluoronaphth-1-yl)-6-isopropylpyrimidine nor a cardiovascular effect is likely to contribute to the inverted U-shape dose-response curve for penile erections.
Journal ArticleDOI
Synthesis and Biological Evaluation of 3-Biphenyl-4-yl-4-phenyl-4H-1,2,4-triazoles as Novel Glycine Transporter 1 Inhibitors
Takashi Sugane,Takahiko Tobe,Wataru Hamaguchi,Itsuro Shimada,Kyoichi Maeno,Junji Miyata,Takeshi Suzuki,Tetsuya Kimizuka,Atsuyuki Kohara,Morita Takuma,Hitoshi Doihara,Kyouko Saita,Masaki Aota,Masako Furutani,Yoshiaki Shimada,Noritaka Hamada,Shuichi Sakamoto,Shin-ichi Tsukamoto +17 more
TL;DR: The preparation and evaluation of a novel series of glycine transporter 1 (GlyT1) inhibitors derived from a high-throughput screening hit revealed that 6p had excellent oral bioavailability and ameliorated learning impairment in passive avoidance tasks in mice.